A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - Trial 2022-002441-18
Access comprehensive clinical trial information for 2022-002441-18 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca AB and is currently Ongoing. The study focuses on Chronic Obstructive Pulmonary Disease (COPD).
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2022-002441-18
Ongoing
Trial Details
EU Clinical Trials Register • 2022-002441-18
A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study Focus
Sponsor & Location
AstraZeneca AB
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1. Confirmed primary diagnosis of moderate to severe COPD as per FEV1/FVC < 0.7, and post-BD FEV1 ≥ 25% predicted)
ICD-10 Classifications
Other chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease, unspecified
Other specified chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
Chronic obstructive pulmonary disease with acute lower respiratory infection
Data Source
EU Clinical Trials Register
2022-002441-18
Non-Device Trial